美国HIV感染者乙型肝炎核心抗体阳性者换用无HBV活性抗逆转录病毒治疗后HBV再激活
既往HBsAg阳性且抗-HBs阴性者再激活率较高。
要点
- 抗-HBc阳性/HBsAg阴性HIV感染者换用无HBV活性方案后HBV再激活总体风险较低。
- 中位再激活时间8.9个月,需在换药后监测HBV DNA和HBsAg。
- 既往HBsAg阳性且抗-HBs阴性者再激活风险更高。
核心结论
- 在抗-HBc阳性/HBsAg阴性的HIV感染者中,从含HBV活性药物换用无HBV活性方案后HBV再激活总体风险似乎较低。
关键数值与推荐
- HBV再激活定义为换药后任何时间检测到HBV DNA或HBsAg阳性。
- 含HBV活性抗逆转录病毒药物包括拉米夫定、恩曲他滨或替诺福韦。
临床怎么用
- 对于抗-HBc阳性/HBsAg阴性的HIV感染者,考虑换用无HBV活性方案时可参考本结果进行医患沟通。
- 换药后应关注HBV再激活风险,尤其对远期HBsAg阳性且抗-HBs阴性者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One in 3 people with human immunodeficiency virus (HIV-1; PWH) are hepatitis B (HBV) core antibody positive (anti-HBc+) and surface antigen negative (HBsAg-) suggesting prior exposure. HBV reactivation can occur in this group if nucleos(t)ide reverse transcriptase inhibitor antiretrovirals (ARV) active against both HIV and HBV are stopped. We describe HBV reactivation in anti-HBc+/HBsAg- PWH following switch from ARV with HBV activity to ARV without HBV activity. METHODS: We identified an at-risk cohort of 5986 anti-HBc+ participants switched from HBV-active to non-HBV-active ARV on or before 31 December 2023 and HBsAg- on the most recent result preceding switch from 63 153 PWH in the Veterans Aging Cohort Study. We defined HBV reactivation as HBV DNA detection or HBsAg+ result at any time following switch. HBV-active ARV included lamivudine, emtricitabine, or tenofovir. RESULTS: Forty (0.67%) anti-HBc+/HBsAg- PWH experienced HBV reactivation after switch to non-HBV-active ARV, with median time to reactivation 8.9 months (interquartile range 5.5-26.7). The rate of HBV reactivation was 25.1 per 10 000 person-years (95% confidence interval [CI], 18.4-34.3). Prespecified subgroup analyses revealed higher rates per 10 000 person-years of HBV reactivation in those HBsAg+ in the remote past with no hepatitis B surface antibody positive (anti-HBs+) result (321; 95% CI, 120-855) versus subgroups never previously HBsAg+ or anti-HBs+ (38.0; 95% CI, 22.9-63.0), or anti-HBs+ but never HBsAg+ (17.4; 95% CI, 11.2-27.0). CONCLUSIONS: Overall risk of HBV reactivation appears low after switch from HBV-active to non-HBV-active ARV among anti-HBc+ PWH with no prior HBsAg+. Our results inform provider-patient discussion about HBV reactivation risk when considering ARV switching.
引用
- Denyer RV, Tate JP, Benator DA, et al. Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity. Clin Infect Dis. 2026. PMID: 41848012. doi:10.1093/cid/ciag001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。